Loading…
5 companies · GEL, thousands · columns ordered by revenue
Only 3 of 5 peers filed FY2024. Switch to FY2021 (5 of 5).
| Line item | Medparma Plus | Medpoli | Em Pharma | Sakhalkho Aptiaki | Sakartvelos Parmatsevtu… |
|---|---|---|---|---|---|
| Total Revenue | 4,916 | 4,660 | 4,216 | — | — |
| Total COGS | -1,946 | -1,737 | -3,807 | — | — |
| Gross Profit | 2,970 | 2,923 | 409 | — | — |
| Gross Margin | 60.4% | 62.7% | 9.7% | — | — |
| Total Operating Expenses | -1,847 | -3,223 | -456 | — | — |
| EBITDA | 1,123 | -300 | -47 | — | — |
| EBITDA Margin | 22.8% | -6.4% | -1.1% | — | — |
| Total D&A | -218 | -47 | -2 | — | — |
| EBIT / Operating Income | 905 | -347 | -49 | — | — |
| Total Interest Income | 76 | — | — | — | — |
| Total Interest Expense | -5 | -32 | — | — | — |
| Total Other Income | 40 | 406 | 24 | — | — |
| Profit Before Tax | 1,016 | 28 | -26 | — | — |
| Total Income Tax | -75 | 0 | 0 | — | — |
| Net Profit / (Loss) | 940 | 28 | -26 | — | — |
| Net Margin | 19.1% | 0.6% | -0.6% | — | — |
Not every picked company reports every selected year — FY2024: no filing for Sakhalkho Aptiaki and Sakartvelos Parmatsevtu…. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Medparma Plus | Pharma | 22.8% | 65th pct | 110 |
| Em Pharma | Pharma | -1.1% | 13th pct | 110 |
| Medpoli | Pharma | -6.4% | 5th pct | 110 |
| Sakhalkho Aptiaki | Pharma | — | no FY data | 110 |
| Sakartvelos Parmatsevtu… | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.